<DOC>
	<DOCNO>NCT00665457</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . PURPOSE : This phase II clinical trial study biomarkers side effect woman receive chemotherapy celecoxib stage II stage III breast cancer remove surgery .</brief_summary>
	<brief_title>Biomarkers Women Receiving Chemotherapy Celecoxib Stage II Stage III Breast Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : - To determine safety efficacy four course neoadjuvant chemotherapy comprise docetaxel , capecitabine , celecoxib follow doxorubicin hydrochloride , cyclophosphamide , celecoxib treatment woman resectable stage II III breast cancer . - To determine mRNA protein level thyraidylate synthase ( TS ) , thymidine phosphylase ( TP ) , vascular endothelial growth factor ( VEGF ) , Multi-Drug Resistance Protein 1 ( MDR-1 ) , cyclooxygenase-2 ( COX-2 ) , matrix metalloproteinase-2 ( MMP-2 ) tumor tissue prior follow treatment . - To correlate baseline expression TS , TP , VEGF , MDR , COX-2 , MMP-2 tumor response measure physical exam , breast MRI , breast ultrasound , mammography , pathologic response . - To determine polymorphisms gene encode protein also correlate outcome , correlation find specific molecular marker clinical outcome . OUTLINE : - Neoadjuvant chemotherapy : Patients receive docetaxel IV 1 hour day 1 , 8 , 15 , oral capecitabine twice daily day 1-14 , oral celecoxib twice daily day 1-21 . Courses repeat every 3 week 4 course absence disease progression unacceptable toxicity . Patients receive doxorubicin hydrochloride IV cyclophosphamide IV daily day 1 , oral celecoxib twice daily day 1-14 , filgrastim subcutaneously daily day 3-10 . Courses repeat every 2 week 4 course absence disease progression unacceptable toxicity . Celecoxib stop one week prior surgery . - Surgery : Patients undergo definitive surgery ( either modify radical mastectomy lumpectomy combine axillary node dissection ) . Patients may also undergo adjuvant radiotherapy hormonal therapy discretion multidisciplinary breast team . Blood collect baseline examine genetic polymorphism associate functional change protein . Tumor tissue obtain needle biopsy baseline , second course docetaxel/capecitabine/celecoxib , surgical resection . Molecular marker protein expression assess immunohistochemistry use fluorescence-image analysis real-time reverse-transcriptase PCR . Patients undergo image comprise dynamic MRI , ultrasound , mammogram baseline first second 4 course chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologic evidence invasive breast cancer Stage IIIII disease Resectable disease Must primary tumor estimate mammogram , ultrasound palpation â‰¥ 3 cm and/or palpable axillary node &gt; 1 cm neoadjuvant chemotherapy appropriate Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify ECOG performance status 01 Absolute granulocyte count &gt; 2,000/mm^3 Platelet count &gt; 100,000/mm^3 Serum bilirubin &lt; 1.5 time upper limit normal ( ULN ) Serum creatinine &lt; 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study therapy No allergy sulfa medication , aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) No uncontrolled concurrent illness might jeopardize patient 's ability receive chemotherapy program outline protocol , include follow : Active infection require intravenous antibiotic Symptomatic congestive heart failure Unstable angina pectoris Serious , uncontrolled cardiac arrhythmia No prior malignancy except adequately treat basal cell squamous cell skin cancer , noninvasive carcinoma , cancer patient diseasefree least 5 year PRIOR CONCURRENT THERAPY : No prior chemotherapy radiation therapy ipsilateral breast cancer . At least 2 week since prior treatment cyclooxygenase ( COX ) 2 inhibitor No concurrent sorivudine brivudine treat herpes simplex herpes zoster viral infection No concurrent participation another therapeutic clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>